SLC5A2 and type 2 diabetes mellitus: NICE guidelines recommend SGLT-2 inhibitors with metformin as second line oral antidiabetic treatment for people with T2DM and cardiovascular disease CVD), or at high risk of CVD; however, for the broader population with T2DM without these indications, these guidelines recommend sulfonylureas, DPP-4 inhibitors, or SGLT-2 inhibitors along with metformin